keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Rotigaptide TFA(355151-12-1 free base) 是一种新型的 Cx43 特异性调节剂,是一种有效的 AAP。 Rotigaptide 可防止 Cx43 介导的间隙连接通讯的解偶联,并使急性代谢应激期间的细胞间通讯正常化。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,310 | 现货 | ||
5 mg | ¥ 3,860 | 现货 | ||
10 mg | ¥ 5,530 | 现货 | ||
25 mg | ¥ 8,530 | 现货 | ||
50 mg | ¥ 11,500 | 现货 | ||
100 mg | ¥ 15,500 | 现货 | ||
500 mg | ¥ 29,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 5,270 | 现货 |
产品描述 | Rotigaptide TFA(355151-12-1 free base) is a novel and specific modulator of Cx43 and is a potent AAP. Rotigaptide TFA(355151-12-1 free base) prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress. |
体外活性 | Rotigaptide TFA (100 nM; 24 hours) does not affect INS-1 cell apoptosis itself. Rotigaptide (100 nM; 24 hours) has a positive effect on the cycloheximide-mediated decrease in Cx43 protein levels in cultured neonatal ventricular myocytes. And it obviously decreases apoptosis in cytokine-exposed cells ~10% at IL-1b concentrations above 15 pg/ml in rat insulin-producing INS-1 cells [1][2]. |
体内活性 | Rotigaptide TFA (intravenous administration; 300 mg/kg; single dose) treatment in mice and rats does not cause toxicity in either species. Rotigaptide (continuous intravenous infusion; 5-14 days) in rats (100 mg/kg) and dogs (10 mg/kg) is well tolerated and produces no compound-related effects or histological toxicological findings in escalating dose studies [3]. |
别名 | Rotigaptide TFA |
分子量 | 731.67 |
分子式 | C30H40F3N7O11 |
CAS No. | T16790L |
keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 7.32 mg/mL (10 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.3667 mL | 6.8337 mL | 13.6674 mL | 34.1684 mL |
5 mM | 0.2733 mL | 1.3667 mL | 2.7335 mL | 6.8337 mL | |
10 mM | 0.1367 mL | 0.6834 mL | 1.3667 mL | 3.4168 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Rotigaptide TFA(355151-12-1 free base) T16790L Cytoskeletal Signaling Gap Junction Protein Rotigaptide TFA(355151 12 1 free base) Rotigaptide TFA Rotigaptide TFA(355151121 free base) Inhibitor inhibitor inhibit